Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

There were no significant differences between the groups with increased BMD (gain in BMD equal or exceeding the LSC) vs. no change in BMD after IVMP treatment as far as the selected characteristics were considered (Table 4).Comparison of selected characteristics of patients with and without increase of BMD (gain in BMD equal to or exceeding the LSC) in the lumbar spine and/or femoral neck after IVMP therapyIncrease of BMD 15/35 (43%)No change of BMD 20/35 (57%)p valueAge (years), mean±SD51 ± 1446 ± 110.77Women, n (%)12 (80%)17 (85%)1.00Women after menopause, n (%)5 (33%)7 (35%)1.00BMI (kg/m2), mean±SD26 ± 426 ± 50.67Duration of GO (months), mean ± SD13 ± 3821.5 ± 920.13Duration of euthyreosis before IVMP (months), mean ± SDa2.6 ± 1.4b2.8 ± 2.9c0.31Smokers, n (%)7 (47%)8 (40%)0.74TSH (µIU/mL), mean ± SD1.1 ± 1.11.4 ± 1.30.43Baseline 25(OH)D (ng/mL), mean ± SD20.1 ± 1018.5 ± 70.27Vitamin D deficiency, n (%)9 (60%)9 (45%)0.50Vitamin D suboptimal level, n (%)4 (27%)9 (45%)0.31Vitamin D optimal level, n (%)2 (13%)2 (10%)1.00Osteopenia (−1.0 to >−2.5) before IVMP, n (%)5 (33%)7 (35%)1.00Values are presented as mean or as otherwise indicatedBMD bone mineral density, BMI body mass index, TSH thyroid-stimulating hormone, GO Graves’ orbitopathy, IVMP intravenous methylprednisolone, 25(OH)D 25-hydroxyvitamin D, Vitamin D deficiency 25(OH)D level below 20 ng/mL, Vitamin D suboptimal level 25(OH)D level 20 to 30 ng/mL, Vitamin D optimal level 25(OH)D level above 30 ng/mLaDuration of euthyreosis before IVMP is presented for 21 patients with Graves’ disease using thyrostatic drugsbMean duration of euthyreosis before IVMP assessed in 12 out of 21 former hyperthyroid patients in whom the increase of BMD was foundcMean duration of euthyreosis before IVMP assessed in 9 out of 21 former hyperthyroid patients in whom the increase of BMD was not found

Source: Effect of IVMP treatment on BMD. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Twenty-one patients were treated with antithyroid drugs (alone or according to a “block and replace” schedule) and 13 patients received levothyroxine: 9 patients with Graves’ disease who were at least 6 months after the last radical treatment (6 patients after radioiodine therapy and 3 patients after thyroidectomy) and 4 patients with Hashimoto thyroiditis.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Therapy of moderate-to-severe Graves’ orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density

Study design awaiting verification · Endocrine · 2018

Original publication title

Therapy of moderate-to-severe Graves’ orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density

Joanna Rymuza; Michał Popow; Zuzanna Żurecka; Jerzy Przedlacki; Tomasz Bednarczuk; Piotr Miśkiewicz

© The Author(s) 2018

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

IVMP given in weekly intravenous pulses does not lead to loss of BMD of the lumbar spine and the femoral neck.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To evaluate the influence of intravenous methylprednisolone (IVMP) pulse administration on bone mineral density (BMD) of the lumbar spine and the femoral neck in patients with moderate-to-severe Graves’ orbitopathy (GO).

Source: Purpose

Abstract: What methods does the paper describe?

Thirty-five patients with GO in euthyreosis were treated with 12 IVMP pulses (6 × 0.5 g, 6 × 0.25 g on a weekly schedule). Supplementation with 1.0 g of calcium and 800 IU of vitamin D was initiated in all patients before beginning therapy. BMD of the lumbar spine (L1: L4) and the femoral neck were assessed at baseline and after the last IVMP pulse using dual-energy X-ray absorptiometry. To determine differences in BMD between values at baseline and after treatment, we used the least significant change (LSC) methodology.

LSC values were calculated to be 3 and 5% for the lumbar spine and the femoral neck, respectively. Change in BMD equal to or exceeding the LSC was assessed as either increase or decrease of BMD. We then compared pre-treatment and post-treatment mean BMD values at the lumbar spine and the femoral neck.

Source: Methods

Abstract: Results

We did not observe a decrease of BMD at any site equal to or exceeding the LSC. We found an increase of BMD in at least one measurement site equal to or exceeding the LSC value in 43% of patients, mostly in the lumbar spine (31%). Mean femoral neck BMD did not change while mean lumbar BMD increased.

Source: Results

Abstract: Conclusions

IVMP given in weekly intravenous pulses does not lead to loss of BMD of the lumbar spine and the femoral neck.

Source: Conclusions
Authors’ abstract

Purpose

To evaluate the influence of intravenous methylprednisolone (IVMP) pulse administration on bone mineral density (BMD) of the lumbar spine and the femoral neck in patients with moderate-to-severe Graves’ orbitopathy (GO).

Methods

Thirty-five patients with GO in euthyreosis were treated with 12 IVMP pulses (6 × 0.5 g, 6 × 0.25 g on a weekly schedule). Supplementation with 1.0 g of calcium and 800 IU of vitamin D was initiated in all patients before beginning therapy. BMD of the lumbar spine (L1: L4) and the femoral neck were assessed at baseline and after the last IVMP pulse using dual-energy X-ray absorptiometry. To determine differences in BMD between values at baseline and after treatment, we used the least significant change (LSC) methodology.

LSC values were calculated to be 3 and 5% for the lumbar spine and the femoral neck, respectively. Change in BMD equal to or exceeding the LSC was assessed as either increase or decrease of BMD. We then compared pre-treatment and post-treatment mean BMD values at the lumbar spine and the femoral neck.

Results

We did not observe a decrease of BMD at any site equal to or exceeding the LSC. We found an increase of BMD in at least one measurement site equal to or exceeding the LSC value in 43% of patients, mostly in the lumbar spine (31%). Mean femoral neck BMD did not change while mean lumbar BMD increased.

Conclusions

IVMP given in weekly intravenous pulses does not lead to loss of BMD of the lumbar spine and the femoral neck.

Publication and source details

Original title: Therapy of moderate-to-severe Graves’ orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density

Joanna Rymuza; Michał Popow; Zuzanna Żurecka; Jerzy Przedlacki; Tomasz Bednarczuk; Piotr Miśkiewicz

Endocrine · 2018

© The Author(s) 2018https://creativecommons.org/licenses/by/4.0/Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T20:04:48.410182+00:00

DOI: 10.1007/s12020-018-1823-x · PMC6531386